Median Technologies SA presented strategic updates on its eyonis LCS software as a medical device for lung cancer screening using low-dose CT. The company said eyonis LCS received FDA 510(k) clearance on Feb. 6, 2026 and is commercially available in the U.S., with CE mark expected in Q2 2026. Median highlighted a non-exclusive distribution agreement with Tempus to integrate eyonis LCS into Tempus Pixel, and outlined a phased U.S. commercialization plan including expansion of its sales organization and initiation of health-economics studies in 2026. The presentation also cited 2025 revenue of €23.5 million, a record backlog of €76.6 million, and cash of €18.2 million as of Dec. 31, 2025. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Median Technologies SA published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.